Therapeutic potential of iron modulating drugs in a mouse model of multiple system atrophy

JJ Shukla; N Stefanova; AI Bush; G McColl; DI Finkelstein; EJ McAllum

Journal article

Therapeutic potential of iron modulating drugs in a mouse model of multiple system atrophy

JJ Shukla, N Stefanova, AI Bush, G McColl, DI Finkelstein, EJ McAllum

Neurobiology of Disease | ACADEMIC PRESS INC ELSEVIER SCIENCE | Published : 2021

DOI: 10.1016/j.nbd.2021.105509

Abstract

Multiple System Atrophy (MSA) is a rare neurodegenerative synucleinopathy which leads to severe disability followed by death within 6–9 years of symptom onset. There is compelling evidence suggesting that biological trace metals like iron and copper play an important role in synucleinopathies like Parkinson's disease and removing excess brain iron using chelators could slow down the disease progression. In human MSA, there is evidence of increased iron in affected brain regions, but role of iron and therapeutic efficacy of iron-lowering drugs in pre-clinical models of MSA have not been studied. We studied age-related changes in iron metabolism in different brain regions of the PLP-αsyn mice ..

View full abstract

University of Melbourne Researchers

Ashley Bush Author

Gawain McColl Author

David Finkelstein Author

Related Projects (3)

Iron, ferroptosis and the biology of ageing

This project aims to determine how and when regulation of iron is lost. Failing iron metabolism during life may dictate the rate of ageing b..

BRAIN IRON IMAGING FOR ALZHEIMER’S DISEASE (AIBL-ADIRON STUDY)

Iron accumulation in the brain is linked to Alzheimer's disease. New Magnetic Resonance Imaging scans allow us to painlessly image the brain..

UNDERSTANDING HOW CELLS STORE AND USE IRON

Grants

Awarded by Australian Research Council

Funding Acknowledgements

[ "JJS: Employment: The Florey Institute of Neuroscience and Mental Health, Australia. MSA Coalition Seed Grant.", "NS: Employment: Medical University of Innsbruck, Austria.", "Grants: Austrian Science Fund (FWF) F4414, W1206-08.", "AIB-Employee: Florey Institute of Neuroscience & Mental Health; University of Melbourne.", "Grants: NHMRC -GNT1103703. GNT1101533.", "Holds equity: Alterity Biotechnology Ltd., Cogstate Ltd., Mesoblast Ltd., Collaborative Medicinal Development LLC.", "Payed consultant: Collaborative Medicinal Development Pty Ltd.", "GM: Employment: The Florey Institute of Neuroscience and Mental Health, Australia.", "Grants: Australian Research Council Discovery Projects (DP180101248 and DP200100110) and a Human Frontiers of Science Research Grant (RGP0022).", "DIF: Employment: The Florey Institute of Neuroscience and Mental Health, Australia.", "Grants: National Health and Medical Research Council: APP11567744; APP1144724, APP1145686, MJFOX 18619; MSA Coalition Seed Grant.", "Board: Parkinsons Victoria, ABN: 59604001176.", "EJM: Employment: The Florey Institute of Neuroscience and Mental Health, Australia.", "Grants: NHMRC-ARC Dementia Research Development Fellowship (GNT1105791); MSA Coalition Seed Grant.", "This work was supported by seed research grant (#2017-10-009) received from the Multiple System Atrophy Coalition, USA and grant of the Austrian Science Fund (FWF) F4414." ]